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Abstract
Background: Cervical cancer is the third most common cancer among women worldwide, and in Nigeria it is the
second most common female cancer. Cervical cancer is an AIDS-defining cancer; however, HIV only marginally
increases the risk of cervical pre-cancer and cancer. In this study, we examine the risk factors for cervical pre-cancer
and cancer among HIV-positive women screened for cervical cancer at two medical institutions in Abuja, Nigeria.
Methods: A total of 2,501 HIV-positive women participating in the cervical cancer screen-and-treat program in
Abuja, Nigeria consented to this study and provided socio-demographic and clinical information. Log-binomial
models were used to calculate relative risk (RR) and 95% confidence intervals (95%CI) for the risk factors of cervical
pre-cancer and cancer.
Results: There was a 6% prevalence of cervical pre-cancer and cancer in the study population of HIV-positive
women. The risk of screening positivity or invasive cancer diagnosis reduced with increasing age, with women
aged 40 years and older having the lowest risk (RR=0.4; 95%CI=0.2–0.7). Women with a CD4 count of 650 per mm
3
or more also had lower risk of screening positivity or invasive cancer diagnosis (RR=0.3, 95%CI=0.2–0.6). Other
factors such as having had 5 or more abortions (RR=1.8, 95%CI=1.0–3.6) and the presence of other vaginal wall
abnormalities (RR=1.9, 95%CI=1.3–2.8) were associated with screening positivity or invasive cancer diagnosis.
Conclusion: The prevalence of screening positive lesions or cervical cancer was lower than most previous reports
from Africa. HIV-positive Nigerian women were at a marginally increased risk of cervical pre-cancer and cancer.
These findings highlight the need for more epidemiological studies of cervical cancer and pre-cancerous lesions
among HIV-positive women in Africa and an improved understanding of incidence and risk factors.
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Background
In 2008, cervical cancer was the third most common
cancer among women and the seventh most common
cancer overall with 530,000 new cases and 275,000
deaths reported [1]. Women in Sub-Saharan Africa are
disproportionately affected, where it is the most com-
mon cancer in women, accounting for 13% of all female
cancers [1,2]. In Nigeria, it is the second most common fe-
male cancer after breast cancer, with an age standardized
incidence rate of 34.5 cases per 100,000 women in 2010 [3].
Virtually all cases of cervical pre-cancer and cancer
are associated with a high-risk human papillomavirus
(hrHPV) infection, with types 16 and 18 reported to ac-
count for the majority of cases [4,5]. However, only
about 12% of individuals with persistent hrHPV infec-
tion go on to develop cervical pre-cancer and cancer.
Hence, hrHPV infection can a cause of cervical cancer,
but is not the exclusive cause. In addition to hrHPV,
other factors impact progression, from persistent hrHPV
infection to cervical pre-cancer to cancer. These include
smoking, parity, education, diet, physical inactivity, sex-
ual behavior and use of oral contraceptives [6,7]. Other
factors, including population growth and aging, are also
contributing to the rising burden of cervical cancer in
developing countries [8].
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Centers for Disease Control and Prevention (CDC) has
classified cervical cancer, Kaposi sarcoma and non-
Hodgkin’s lymphoma as AIDS-defining cancers because
of their close association with HIV infection [2]. How-
ever, unlike the latter two types of cancer, the risk of cer-
vical cancer is only marginally elevated at best among
HIV-infected women [9-13]. Furthermore, compared
with other AIDS-defining cancers, the incidence of cer-
vical cancer has not decreased substantially with increas-
ing use of anti-retroviral therapy, which suggests that
the role of immunosuppression in the progression to in-
vasive cancer may be marginal [9,14-18].
In developed countries, some 75% of women are
screened—typically by Papanicolaou staining (Pap smears)
and more recently by human papillomavirus (HPV) DNA-
based tests—compared with 5% in developing countries
[19]. As a consequence, the incidence of cervical cancer in
developed countries has been reduced substantially, in
contrast to developing countries such as Nigeria, where
the incidence has remained stable [3,20]. The choice of
screening method for cervical cancer is also a challenge
for developing countries. Widespread adoption of Pap
smears has not been feasible in developing countries be-
cause of the need for high quality cytology equipment, la-
boratories and well-trained clinicians who can interpret
Pap smear results, the need for multiple hospital visits,
and the need for follow-ups and the recall of patients sev-
eral times [19,21]. HPV DNA testing is expensive, requires
multiple visits and is beyond the resources of most
low- and middle-income countries (LMIC) at the
present time. Other factors, including poor health care
infrastructure, lack of resources and competing needs
for limited health care resources, also mitigate against
widespread adoption of cervical cancer screening in
low resource countries [19].
An alternative cervical cancer screening method that
is recommended for use in developing countries is visual
inspection with acetic acid or Lugol’s iodine (VIA/VILI).
VIA/VILI is an inexpensive test that can be easily
adopted and scaled up in the healthcare system of
LMIC, does not require specialized laboratories or
equipment, can be performed by a wide range of health
care professionals after a short period of training and
does not require several visits by patients [10,16,19,22].
VIA/VILI is increasingly used as a “screen and treat” ap-
proach to cervical cancer screening in LMIC where
treatment for abnormal lesions is performed during one
single clinic visit, thereby minimizing the need of pa-
tients having to attend a follow-up [16,19].
In some countries, donor funding from the President’s
Emergency Plan for AIDS Relief (PEPFAR) and the Glo-
bal Fund has provided the resources and infrastructure
needed to scale up visual inspection with acetic acid
testing (VIA) [16]. For example, Zambia leveraged these
resources, rapidly expanded its VIA model and inte-
grated it into the health care system. This has ensured
the success of the program without placing extra burden
on the health care system, thus maximizing the potential
of the “screen and treat” approach [10,16,22]. VIA is
reported to have 80% sensitivity, 92% specificity, a 10%
positive predictive value and a 99% negative predictive
value [21]. In this paper, we report risk factors for VIA/
VILI positivity among the study’s screened population in
Nigeria.
Methods
Place of study
This study was carried out at the University of Abuja
Teaching Hospital and the National Hospital, both in
Abuja, Nigeria.
Screening population
HIV-positive women older than 18 years of age either on
anti-retroviral therapy (ART) or ART naïve attending
PEPFAR treatment clinics for HIV care were enrolled at
both sites. Participants were women who voluntarily
presented and gave informed consent for cervical cancer
screening.
Screening procedure
After obtaining informed consent, nurses obtained
demographic and clinical information on all participants
and examined the introitus and vulva, noting any abnor-
malities. A bivalve speculum was then introduced into
the vagina for examination of the cervix using a halogen
lamp. The squamo-columnar junction of the cervix
(transformation zone) was identified and any secretions
or exudate cleaned off before a nurse applied a cotton
wool swab soaked in 5% acetic acid solution for 3 mi-
nutes. The results of each examination were noted.
Pre-cancerous lesions were defined as being dense
aceto-white lesions with well-defined margins observed
within the vicinity of the transformation zone originat-
ing from the squamo-columnar junction, or if the
whole cervix or cervical growth turned white. A suspi-
cion of cancer was defined as any cervical ulcer or
growth being observed [23]. Following VIA, if there
was any uncertainty about the lesion observed, visual
inspection with Lugol’si o d i n e( V I L I )w a sc o n d u c t e d .A
positive VILI was characterized as being well-defined,
bright yellow iodine non-uptake areas touching the
squamo-columnar junction or close to the cervical os
if the squamo-columnar junction was not seen.
Results of VIA or VILI were classified according to the
International Agency for Research Against Cancer
(IARC) manual and recorded after each test [24]. Posi-
tive areas were mapped on case report forms and the
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gree of extension noted. Digital images (cervigrams) of
the cervix were captured for all screened women regard-
less of the outcome of VIA using off-the-shelf digital
cameras (Canon Powershot SX20 IS®). Cervigrams were
used to provide patients with immediate feedback on the
results of their examination, and were saved on a com-
puter as part of the client’s record. They were subse-
quently reviewed by a consulting gynecologist for quality
assurance purposes.
Women with confirmed VIA or VILI positive results
were offered immediate treatment with cold coagulation.
This is an ablative therapy used for treatment of
intraepithelial neoplasia that is not suspected of being
cancerous, not covering more than 75% of the cervix, is
not disappearing into the endo-cervical canal, and the
squamo-columnar junction is fully visible. A patient with
a cervix suspicious for cancer or with intraepithelial neo-
plasia was ineligible for cold coagulation according to
predefined criteria. These women were referred to the
gynecology clinic to undergo colposcopy and biopsy to
confirm probable cancer diagnosis and to receive further
treatment, as is standard practice in screen and treat
programs [23].
Quality assurance
At the end of every week, quality assurance meetings were
held with nurses and the consulting gynecologist to review
all cervigrams taken during the week, with the aim of
assessing the nurses’ visual detection skills and referral de-
cisions. In those cases where there was a missed diagnosis
of clinical relevance the patient was recalled.
Statistical analysis
Relative risk and 95% confidence intervals (95%CI) were
calculated using log-binomial regression models [25,26].
The p-value for trend for ordinal variables was calculated
using the median value of each category. A liberal criter-
ion for the selection of potential confounders and possible
independent risk factors was employed; all variables that
were significant in the univariate models at p≤0.20 were
included in the multivariate models [27]. We divided the
continuous variables (age and last CD4 count) by mul-
tiples of five, which corresponded approximately to
quartiles of the age distribution. We investigated pos-
sible non-linearity in the log-binomial models between
screening status and continuous variables (age, age at first
sexual intercourse, total number of pregnancies, total
number of abortions and last CD4 count) using stepwise
restricted cubic splines. A likelihood ratio test was used to
compare the log-linear model to the model with any non-
linear terms that were selected in the smoothing process
[28,29]. All data analysis was performed using SAS 9.3
(SAS Institute; Cary, NC, USA).
Results
Socio-demographic and clinical characteristics of the
study participants are shown in Tables 1 and 2. A total
of 2,501 HIV-infected women on ART were screened be-
tween 2010 and 2012. The mean age and standard devi-
ation (SD; the second number) was 35 (7) years. The
mean number of sexual partners (SD) was 1 (1). The
mean age (SD) at first sexual intercourse was 19 (4)
years. The mean (SD) number of pregnancies was 4 (2).
The mean (SD) number of abortions experienced was 2
(2). Christianity was the most common religion, with
84% of the women identifying as Christians. The level of
education within this group of women was high, with
77% having secondary education or higher. The majority
of women, 52%, were married at the time of the study.
Most women, 77%, had CD4 counts above 300; the me-
dian CD4 count was 451 cells per mm
3. The majority of
the HIV-infected women, 86%, were asymptomatic and
were classified as having Stage 1 at baseline as defined
by World Health Organization guidelines [30].
Few participants, 6%, had a positive screening test re-
sult or a confirmed diagnosis of invasive cervical cancer.
Women with positive results and invasive cancer were
grouped together for analysis; although we recognize
that a positive VIA/VILI result does not necessarily
equate to a cervical cancer diagnosis. The results of the
univariate associations are shown in Table 3. The me-
dian age of women with a positive screening result/inva-
sive cancer was 32 years compared with a median of 35
years in women with a negative screening result (ptrend <
0.0001). The median number of pregnancies among
women with a positive VIA result/invasive cancer was 3
compared with 4 pregnancies in women with a negative
(ptrend=0.03). A greater proportion of women with VIA
positive lesions were Christians (p=0.04). Women
with a positive screening result/invasive cancer also
had a higher proportion of vaginal wall abnormality
(p=0.0006). The most recent CD4 count prior to
screening was significantly higher among women with
a negative screening result compared with women with a
positive screening result/invasive cancer (p <0.0001). The
results of the multivariate analyses are shown in Table 3.
The risk of screening positivity or invasive cancer diagno-
sis decreased with increasing age, with women aged 40
years and older having the lowest risk (RR=0.4; 95%
CI=0.2–0.7). Women with a CD4 count of 650 per mm
3
or more had the lowest risk of screening positivity or inva-
sive cancer diagnosis (RR=0.3, 95%CI=0.2–0.6). Other in-
dependent risk factors, such as having had five or more
abortions (RR=1.8, 95%CI=1.0–3.6) and the presence of
other vaginal wall abnormalities (RR=1.9, 95%CI=1.3–2.8),
were associated with screening positivity or invasive
cancer diagnosis. There were no independent associa-
tions with age at first sexual intercourse or multiple
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ship between age and screening status, where risk was
slightly elevated up to age 35 and then declined dra-
matically up to age 50, after which no further decrease
in risk was apparent (Figure 1).
Discussion
In this study of cervical cancer risk factors in HIV-
positive Nigerian women, we found a 6% prevalence of
cervical pre-cancer and cancer. This finding is inconsist-
ent with previous reports from other Sub-Saharan Afri-
can countries where a higher prevalence of pre-cancer
and cancer has been reported [31-38]. Studies conducted
in Rwanda, Kenya, South Africa, Uganda and Zambia
reported prevalence of cervical pre-cancer and cancer
among HIV-positive women of 24.3%, 26.7%, 66.3%,
73.0% and 76%, respectively [31-35].
In order to address these inconsistencies, knowing that
the age-standardized incidence of cervical cancer in
Nigeria is 34.5 per 100,000 people/year and this has not
changed significantly in the last few decades [3], that
20% of cervical abnormalities if untreated progress to
carcinoma, and assuming that the average duration from
a cervical abnormality to cancer is about 15 years given
that the average duration of cervical cancer from the
time of infection with the HPV to cervical cancer has
been estimated at 30 years [39], it is possible to estimate
the expected prevalence of cervical abnormalities. The
relationship between the incidence, I, and the point
prevalence of disease, p, can be used to calculate the
expected prevalence of cervical abnormalities as follows:
p ¼ I D
1þI D, where  D is the average duration of the disease
[40]. Applying this formula and based on the assump-
tions made above, an expected prevalence of 2.5% is
obtained. Further assumptions based on the sensitivity
of VIA/VILI will increase this prevalence estimate. It is
Table 1 Socio-demographic characteristics of HIV-infected
women (n=2,501)
n (%) Missing (%)
Age category (years) 11 (0.4)
<30 504 (20)
30–34 696 (28)
35–39 663 (27)
≥40 627 (25)
Age at first sexual intercourse (years) 29 (1.2)
<15 156 (6)
15–19 1242 (50)
20–24 856 (35)
≥25 218 (9)
Number of sexual partners 10 (0.4)
≤2 2400 (96)
3–4 68 (3)
≥5 23 (1)
Total number of pregnancies
1 1 (0.04)
0–2 722 (29)
3–4 827 (33)
5–6 571 (23)
≥7 380 (15)
Total number of abortions 6 (0.2)
0–2 1873 (75)
3–4 445 (18)
≥5 177 (7)
Religion 5 (0.2)
Islam 404 (16)
Christian 2092 (84)
Education 2 (0.1)
None 150 (6)
Quaranic 27 (1)
Primary 402 (16)
Secondary 773 (31)
Tertiary 1147 (46)
Marital Status 0 (0)
Single 443 (18)
Married 1297 (52)
Widowed 537 (21)
Divorced 207 (8)
Cohabiting 17 (1)
Contraceptives use
2 3 (0.1)
Yes 657 (26)
No 1841 (74)
Hormonal contraceptives
3 0 (0)
Yes 29 (1)
No 2472 (99)
Table 1 Socio-demographic characteristics of HIV-infected
women (n=2,501) (Continued)
Intrauterine devices 1 (0.04)
Yes 32 (1)
No 2468 (99)
Barrier contraceptives 0 (0)
Yes 554 (22)
No 1947 (78)
Tubal ligation 1 (0.04)
Yes 11 (0)
No 2489 (100)
1Total number of pregnancies is defined as pregnancies carried after 28-weeks,
regardless of outcome.
2Contraceptive use refers to history of contraceptive use.
3Hormonal contraceptives includes oral contraceptives, hormonal injections
and intradermal implants.
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assumptions, the prevalence of cervical abnormality ob-
served in the study could have been easily obtained. For
example, if only 10% of untreated cervical abnormalities
in this setting progress to frank cancer, the expected
prevalence of cervical abnormalities would be 4.9%. It is
noted that the incidence of cervical cancer in East Africa
is about 50% higher than in West Africa [1]. For preva-
lence to be as high as that reported in some of the other
studies in Sub-Saharan African, such as 27% as reported
in a recent study among HIV-infected women in Kenya,
the cervical cancer incidence rate would have to be
about 493/100,000 people/year; approximately 10-fold
greater than what has been observed in African
population-based registries. Thus, it is probable that
the cervical pre-cancer and cancer prevalence obtained
in these other studies were over-estimated and the re-
sults of the present study are likely to be much closer
to the true value.
The higher prevalence reported by some of these other
studies may also be partly explained by differences in the
sexual practices of the women studied [2]. Having mul-
tiple sexual partners increases the risk of acquiring HPV,
and in turn, the development of cervical pre-cancer and
cancer. In Cote D’Ivoire, 56% of the women had ≥5 life-
time sexual partners and in South Africa the median
number of sexual partners was 4, while in the present
study 96% of women reported ≤ 2 sexual partners
[2,33,41]. It is, however, unlikely that these differences
are sufficient to account for such high rates of preva-
lence as those reported in some of the previous studies.
The limitations of self-reported sexual practices data are
noted, but it is not believed that this would differ sys-
tematically among Sub-Saharan countries [42].
This study is similar to other studies where participants
are recruited through HIV and ART clinics [5,32,33,43].
The median age of women in this study was similar to that
of women in other studies [32,33,44]. In general, women
in the current study had higher CD4 counts than women
in other studies, as all HIV-infected women in this study
had initiated ART treatment [32,33,44].
The prevalence and incidence of cervical cancer is only
marginally affected by HIV/AIDS [2]. Since the intro-
duction of anti-retroviral therapy, the incidence of cer-
vical cancer has not decreased substantially, unlike that
of other AIDS-defining cancers such as Kaposi’s sarcoma
and non-Hodgkin’s lymphoma. This suggests that im-
munosuppression caused by HIV infection is only mar-
ginally associated, at best, with the progression to
cervical cancer [9,14-18]. The lack of a decrease in the
incidence of cervical cancer in this era of effective ART
is supported by data from HIV/AIDS cohorts in devel-
oped countries [18,45,46]. This finding may be partially
explained by the lack of impact of immunosuppression
on carcinogenetic HPV, a necessary but not sufficient
cause of cervical pre-cancer and cancer [44,47].
The majority of the women in this study were aged be-
tween 30 and 39 (55%), and the median age observed for
an invasive cancer diagnosis or positive screening result
was 32 years, which is about 10 years younger than the
median age of 47 years for cervical cancer diagnosis in
the general population [48]. This result is similar to that
of other studies from Africa, which showed HIV-positive
women presenting with cervical pre-cancer and cancer
at an earlier age. In Kenya and South Africa, HIV-
positive women with invasive cervical cancer were on
average about 10 years younger compared with women
who were HIV-negative [49,50]. One hypothesis is that
unsafe sexual behavior puts women at risk of both HPV
Table 2 Clinical characteristics of HIV-infected women
(n=2,501)
n (%) Missing (%)
BMI (kg/m
2) 1840 (73.6)
<18.5 46 (7)
18.5–24.9 401 (61)
25–29.9 49 (7)
≥30 165 (25)
Vaginal wall abnormality 0 (0)
None 2241 (90)
Other
1 260 (10)
VIA 0 (0)
Negative 2344 (94)
Positive 155 (6)
Invasive cancer 2 (0)
Last CD4 count (per mm
3) 365 (14.6)
<300 490 (23)
300–<450 560 (26)
450–<650 592 (28)
≥650 494 (23)
WHO stage 1118 (44.7)
Stage 1 1185 (86)
Stage 2 104 (7)
Stage 3 84 (6)
Stage 4 10 (1)
ART regimen currently on
2 1008 (40)
TDF-containing ART
3 778 (52)
ZDV-containing ART
4 600 (40)
d4T-containing ART
5 115 (8)
1Other includes discharge, lesion, warts, lesion and warts, warts and discharge,
and other observations.
2All women were on ART, the regimen information here is based on those that
were verified from clinical records.
3TDF: Tenofovir.
4ZDV: Zidovudine.
5d4T: Stavudine.
Ononogbu et al. BMC Public Health 2013, 13:582 Page 5 of 10
http://www.biomedcentral.com/1471-2458/13/582Table 3 Association between socio-demographic and clinical characteristics and a positive cervical screening test
among HIV-infected women
Univariate Multivariate
RR (95%CI) p-value RR (95%CI) p-value
Socio-demographic characteristics
Age category (years) <0.0001* 0.0005*
<30 (ref) 1.0 1.0
30–34 0.8 (0.5–1.1) (0.6–1.3)
35–39 0.6 (0.4–0.9) (0.5–1.1)
≥40 0.3 (0.2–0.5) 0.4 (0.2–0.7)
Age at first sexual intercourse (years) 0.06* 0.05*
<15 (ref) 1.0 1.0
15–19 0.9 (0.5–1.6) 0.8 (0.5–1.3)
20–24 0.7 (0.4–1.3) 0.6 (0.4–1.1)
≥25 0.6 (0.2–1.3) 0.5 (0.2–1.2)
Number of sexual partners 0.2*
≤2 (ref) 1.0
3–4 1.2 (0.5–2.8)
≥5 2.1 (0.7–6.1)
Total number of pregnancies 0.03* 0.1*
0–2 (ref) 1.0 1.0
3–4 0.8 (0.5–1.1) 0.7 (0.5–1.1)
5–6 0.6 (0.4–1.0) 0.6 (0.4–1.1)
≥7 0.7 (0.4–1.1) 0.7 (0.4–1.3)
Total number of abortions 0.06* 0.007*
0–2 (ref) 1.0 1.0
3–4 1.5 (1.0–2.1) 1.7 (1.1–2.5)
≥5 1.4 (0.8–2.4) 1.8 (1.0–3.6)
Religion 0.04 0.09
Islam (ref) 1.0 1.0
Christian 1.7 (1.0–2.8) 1.5 (0.9–2.5)
Education 0.5
None (ref) 1.0
Quaranic 0.8 (0.1–6.3)
Primary (0.5–2.7)
Secondary (0.7–3.4)
Tertiary 1.3 (0.6–2.8)
Marital Status 0.08 1.0
Single (ref) 1.0 1.0
Married 0.5 (0.4–0.8) (0.6–1.2)
Widowed 0.5 (0.3–0.8) (0.6–1.6)
Divorced 0.7 (0.4–1.3) (0.6–1.9)
Cohabiting 0.6 (0.1–4.1) 0.6 (0.1–4.1)
Occupation 0.6
Employed (ref) 1.0
Unemployed (1.4–4.2)
Student (0.4–5.5)
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presentation of HIV-infected women [49]. However,
given the results from HIV cohorts in developed coun-
tries that suggest a limited role of HIV-associated im-
munosuppression in cervical carcinogenesis [18,45,46],
the differences in age between HIV-positive and HIV-
negative people may be a reflection of the lower life ex-
pectancy of persons living with HIV/AIDS in Africa.
The results of this study suggest that HIV-infected
women with higher CD4 cell counts were at a reduced
risk for invasive cancer diagnosis or a positive VIA re-
sult. This result agrees with findings from other studies.
For example, in Rwanda, an inverse association was
found between the CD4 count and cervical pre-cancer
among HIV-infected women [44]. Harris et al. found
that HIV-negative and HIV-positive women with a CD4
cell count of greater than 500 cells per mm
3 had low
incidence of cervical pre-cancer compared with those
with lower CD4 counts [51]. These findings may reflect
competing risks in HIV-positive patients with low CD4
counts, and the need to focus more on immune recon-
stitution in that population. It also appears that once
pre-cancerous lesions develop, disease progression is not
affected by the CD4 count, consistent with the marginal
role previously reported for immunosuppression in dis-
ease progression [52].
We also found the risk for cervical pre-cancer and
cancer to be associated with age (≥40 years) which sup-
ports the natural history of cervical carcinogenesis from
hrHPV infection through cervical dysplasia, pre-cancer
and cancer; having five or more abortions and the pres-
ence of vaginal wall abnormalities suggesting a general-
ized increased risk of sexually transmitted diseases in
women who have cervical pre-cancer and cancer. The
Table 3 Association between socio-demographic and clinical characteristics and a positive cervical screening test
among HIV-infected women (Continued)
Other 1.0 (0.5–2.1)
N/A 1.4 (0.4–5.3)
Contraceptive use 1.0 (0.7–1.4) 1.0
Hormonal
contraceptives
0.6 (0.1–3.8) 0.5
Intrauterine devices 1.5 (0.5–4.5) 0.5
Barrier contraceptives 1.2 (0.8–1.7) 0.4
Clinical characteristics
BMI (kg/m
2) 0.8
<18.5 (ref) 1.0
18.5–24.9 (0.7–1.5)
25–29.9 0.6 (0.2–2.5)
≥30 1.0 (0.5–1.8)
Vaginal wall abnormality 0.0006 0.0007
None (ref) 1.0 1.0
Other 2.0 (1.3–2.9) 1.9 (1.3–2.8)
Last CD4 count (per mm
3) <0.0001* <0.0001*
<300 (ref) 1.0 1.0
300–<450 0.5 (0.3–0.7) (0.3–0.7)
450–<650 0.5 (0.3–0.7) 0.5 (0.3–0.8)
≥650 0.3 (0.2–0.5) 0.3 (0.2–0.6)
WHO stage 1.0
Stage 1 (ref) 1.0
Stage 2 (0.2–1.4)
Stage 3 1.3 (0.6–2.7)
Stage 4 1.6 (0.2–10.2)
ART Regimen currently on 0.6
TDF-containing ART 1.4(1.0–2.0)
ZDV-containing ART (1.0–2.2)
d4T-containing ART 0.9 (0.4–2.1)
*p-value for trend using median value of each category.
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ing status may be due to the natural history of cervical
carcinogenesis where infection needs to persist before
engendering malignant change [53].
As this was a cross-sectional study it was not possible
to explore cause-and-effect relationships. We did not
perform HPV DNA testing, cytology or biopsies to con-
firm the result of visual inspections; as a result, visually
inapparent pre-cancerous lesions could have been
missed. Also, since this study was conducted among
HIV-infected women on ART, the results may not be
generalizable to uninfected women. Nevertheless, we be-
lieve this study demonstrates the risk factors of positive
cervical cancer screening test in this population.
Conclusion
In conclusion, HIV-positive Nigerian women are at a
marginally increased risk for cervical pre-cancer and
cancer. Our study highlight the importance of screening
HIV-positive women in Nigeria for cervical cancer. The
screen and treat approach using VIA/VILI has been
shown to be effective for the detection of cervical pre-
cancer and cancer, and incorporation of immediate treat-
ment where applicable is associated with reduced loss to
follow-up. This can also be rapidly scaled up in resource-
constrained settings and be incorporated into HIV treat-
ment programs. Our results demonstrate the need for
more epidemiological studies of cervical pre-cancer and
cancer among HIV-positive, indeed all women in Africa
and an improved understanding of incidence and risk
factors.
Consent
Written informed consent was obtained from the patient
for publication of this report and any accompanying
images.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
UO conducted the data analysis and drafted the manuscript. MA
implemented the study, collected data, assisted with data analysis and
drafting of the manuscript. ZM implemented the study, collected data,
assisted with data analysis and drafting of the manuscript. IL worked on
study implementation and data collection. RO supervised clinical data
collection and assisted with drafting the manuscript. OO supervised clinical
data collection and assisted with drafting the manuscript. PD supervised
clinical data collection and assisted with drafting the manuscript. DS
supervised data analysis and writing of the manuscript. WB supervised
clinical data collection and assisted with drafting the manuscript. CA
conceived the study, participated in study implementation, data collection,
data analysis and drafting of the manuscript. All authors read and approved
the final manuscript.
Acknowledgments
This work was supported by the UM-Capacity Development for Research in
AIDS Associated Malignancy Grant (D43CA153792) from the National Cancer
Institute and IHV-UM AIDS International Training and Research Program
(D43TW001041) from the Fogarty International Center. The content of this
paper is solely the responsibility of the authors and does not necessarily
represent the official views of the National Cancer Institute or the National
Institutes of Health.
Author details
1Department of Epidemiology, Harvard School of Public Health, Boston, MA
02115, USA.
2Office of Research and Training, Institute of Human Virology,
Abuja, Nigeria.
3National Hospital, Abuja, Nigeria.
4University of Abuja
Teaching Hospital, Gwagwalada, Nigeria.
5Department of Biostatistics,
Harvard School of Public Health, Boston, MA 02115, USA.
6Department of
Epidemiology and Public Health, Institute of Human Virology and
95% Confidence Interval
Age
P
r
e
v
a
l
e
n
c
e
 
r
a
t
i
o
 
f
o
r
 
a
b
n
o
r
m
a
l
 
V
I
A
 
Figure 1 Relationship between age and screening status of HIV-infected women participating in cervical cancer screening in Abuja,
Nigeria 2012.
Ononogbu et al. BMC Public Health 2013, 13:582 Page 8 of 10
http://www.biomedcentral.com/1471-2458/13/582Greenebaum Cancer Centre, University of Maryland School of Medicine,
Baltimore, MD 21201, USA.
Received: 12 January 2013 Accepted: 5 June 2013
Published: 14 June 2013
References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008
v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10
[Internet]. Lyon, France: International Agency for Research on Cancer; 2010.
2. Mbulaiteye SM, Bhatia K, Adebamowo C, Sasco AJ: HIV and cancer in
Africa: mutual collaboration between HIV and cancer programs may
provide timely research and public health data. Infectious Agents and
Cancer 2011, 6(1):16.
3. Jedy-Agba E, Curado MP, Ogunbiyi O, Oga E, Fabowale T, Igbinoba F,
Osubor G, Otu T, Kumai H, Koechlin A: Cancer incidence in Nigeria: A
report from population-based cancer registries. Cancer Epidemiology 2012,
36(5):e271–e278.
4. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S: Human
papillomavirus types in invasive cervical cancer worldwide: a meta-
analysis. Br J Cancer 2003, 88(1):63–73.
5. Vuyst HD, Ndirangu G, Moodley M, Tenet V, Estambale B, Meijer CJ, Snijders
PJ, Clifford G, Franceschi S: Prevalence of human papillomavirus in
women with invasive cervical carcinoma by HIV status in Kenya and
South Africa. International journal of cancer Journal international du cancer
2012, 131(4):949–955.
6. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, Peeling
RW, Ashley R, Smith JS, Snijders PJ, et al: Worldwide human papillomavirus
etiology of cervical adenocarcinoma and its cofactors: implications for
screening and prevention. JN a t lC a n c e rI n s t2006, 98(5):303–315.
7. Castellsague X, Munoz N: Chapter 3: Cofactors in human papillomavirus
carcinogenesis--role of parity, oral contraceptives, and tobacco smoking.
Journal of the National Cancer Institute Monographs 2003, 31(31):20–28.
8. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM: The global burden
of cancer: priorities for prevention. Carcinogenesis 2010, 31(1):100–110.
9. Frisch M, Biggar RJ, Goedert JJ: Human papillomavirus-associated cancers
in patients with human immunodeficiency virus infection and acquired
immunodeficiency syndrome. J Natl Cancer Inst 2000, 92(18):1500–1510.
10. Parham G: Cervical cancer prevention in HIV-infected women in
resource-limited settings. HIV Therapy 2010, 4(6):625–628.
11. De Vuyst H, Lillo F, Broutet N, Smith JS: HIV, human papillomavirus, and
cervical neoplasia and cancer in the era of highly active antiretroviral
therapy. Eur J Cancer Prev 2008, 17(6):545–554.
12. Ellerbrock TV, Chiasson MA, Bush TJ, Sun XW, Sawo D, Brudney K, Wright TC
Jr: Incidence of cervical squamous intraepithelial lesions in HIV-infected
women. JAMA 2000, 283(8):1031–1037.
13. Ahdieh L, Klein RS, Burk R, Cu-Uvin S, Schuman P, Duerr A, Safaeian M,
Astemborski J, Daniel R, Shah K: Prevalence, incidence, and type-specific
persistence of human papillomavirus in human immunodeficiency virus
(HIV)-positive and HIV-negative women. J Infect Dis 2001, 184(6):682–690.
14. Ic HIV, Coutinho RA: Highly active antiretroviral therapy and incidence of
cancer in human immunodeficiency virus-infected adults. J Natl Cancer
Inst 2000, 92(15):1823–1830.
15. Heard I: Prevention of cervical cancer in women with HIV. Curr Opin HIV
AIDS 2009, 4(1):68–73.
16. Mwanahamuntu MH, Sahasrabuddhe VV, Kapambwe S, Pfaendler KS,
Chibwesha C, Mkumba G, Mudenda V, Hicks ML, Vermund SH, Stringer JS,
et al: Advancing cervical cancer prevention initiatives in resource-
constrained settings: insights from the Cervical Cancer Prevention
Program in Zambia. PLoS Med 2011, 8(5):e1001032.
17. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA: AIDS-related cancer and
severity of immunosuppression in persons with AIDS. J Natl Cancer Inst
2007, 99(12):962–972.
18. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E,
Levi F, Jundt G, Fisch T: Cancer risk in the Swiss HIV Cohort Study:
associations with immunodeficiency, smoking, and highly active
antiretroviral therapy. J Natl Cancer Inst 2005, 97(6):425–432.
19. Denny L, Quinn M, Sankaranarayanan R: Chapter 8: Screening for cervical
cancer in developing countries. Vaccine 2006, 24(3):71–77.
20. Jedy-Agba EE, Curado MP, Oga E, Samaila MO, Ezeome ER, Obiorah C,
Erinomo OO, Ekanem IA, Uka C, Mayun A: The role of hospital-based
cancer registries in low and middle income countries-The Nigerian Case
Study. Cancer Epidemiol 2012, 36(5):430–435.
21. Sauvaget C, Fayette JM, Muwonge R, Wesley R, Sankaranarayanan R: Accuracy
of visual inspection with acetic acid for cervical cancer screening.
International journal of gynaecology and obstetrics: the official organ of the
International Federation of Gynaecology and Obstetrics 2011, 113(1):14–24.
22. Sahasrabuddhe VV, Parham GP, Mwanahamuntu MH, Vermund SH: Cervical
cancer prevention in low- and middle-income countries: feasible,
affordable, essential. Cancer Prev Res (Phila) 2012, 5(1):11–17.
23. IARC: Screening Tests.I nCervix Cancer Screening. Volume 10. Lyon, France:
IARC; 2005:59–109.
24. Sankaranarayanan R, Wesley RS: A practical manual on visual screening for cervical
neoplasia. Lyon, France: IARC Press; 2003 [IARC Technical Publication No. 41].
25. Spiegelman D, Hertzmark E: Easy SAS calculations for risk or prevalence
ratios and differences. Am J Epidemiol 2005, 162(3):199–200.
26. Wacholder S: Binomial regression in GLIM: estimating risk ratios and risk
differences. Am J Epidemiol 1986, 123(1):174–184.
27. Maldonado G, Greenland S: Simulation study of confounder-selection
strategies. Am J Epidemiol 1993, 138(11):923–936.
28. Durrleman S, Simon R: Flexible regression models with cubic splines. Stat
Med 2006, 8(5):551–561.
29. Govindarajulu US, Spiegelman D, Thurston SW, Ganguli B, Eisen EA:
Comparing smoothing techniques in Cox models for exposure–response
relationships. Stat Med 2007, 26(20):3735–3752.
30. World Health Organization: Interim WHO clinical staging of HIV/AIDS and HIV/
AIDS case definitions for surveillance: African region. Geneva, Switzerland:
World Health Organization; 2005.
31. Leroy V, Ladner J, De Clercq A, Meheus A, Nyiraziraje M, Karita E, Dabis F:
Cervical dysplasia and HIV type 1 infection in African pregnant women:
a cross sectional study, Kigali, Rwanda. The Pregnancy and HIV Study
Group (EGE). Sex Transm Infect 1999, 75(2):103–106.
32. Memiah P, Mbuthia W, Kiiru G, Agbor S, Odhiambo F, Ojoo S, Biadgilign S:
Prevalence and Risk Factors Associated with Precancerous Cervical
Cancer Lesions among HIV-Infected Women in Resource-Limited
Settings. AIDS research and treatment 2012, 2012:953743.
33. Moodley J, Constant D, Hoffman M, Salimo A, Allan B: Human
papillomavirus prevalence, viral load and pre-cancerous lesions of the
cervix in women initiating highly active antiretroviral therapy in South
Africa: a cross-sectional study. BMC Cancer 2009, 9(1):275.
34. Blossom DB, Beigi RH, Farrell JJ, Mackay W, Qadadri B, Brown DR, Rwambuya S,
Walker CJ, Kambugu FS, Abdul-Karim FW: Human papillomavirus genotypes
associated with cervical cytologic abnormalities and HIV infection in
Ugandan women. J Med Virol 2007, 79(6):758–765.
35. Parham GP, Sahasrabuddhe VV, Mwanahamuntu MH, Shepherd BE, Hicks
ML, Stringer EM, Vermund SH: Prevalence and predictors of squamous
intraepithelial lesions of the cervix in HIV-infected women in Lusaka,
Zambia. Gynecol Oncol 2006, 103(3):1017–1022.
36. Hawes SE, Critchlow CW, Niang MAF, Diouf MB, Diop A, Toure P, Kasse AA,
Dembele B, Sow PS, Coll-Seck AM: Increased risk of high-grade cervical
squamous intraepithelial lesions and invasive cervical cancer among
African women with human immunodeficiency virus type 1 and 2
infections. J Infect Dis 2003, 188(4):555–563.
37. Keita N, Clifford GM, Koulibaly M, Douno K, Kabba I, Haba M, Sylla BS, Van
Kemenade FJ, Snijders PJF, Meijer C: HPV infection in women with and
without cervical cancer in Conakry, Guinea. Br J Cancer 2009, 101(1):202–208.
38. Okonda S, Wright C, Michelow P: The status of cervical cytology in
Swaziland, Southern Africa: a descriptive study. Cytojournal 2009, 6(1):14.
39. Wilbanks GD: Summary of informal discussion on general aspects of
cervical cancer. Cancer Res 1973, 33(6):1382–1384.
40. Rothman K, Greenland S: Modern Epidemiology, 2nd edn. Boston, MA:
Lippincott, Williams and Wilkins; 1998.
41. Horo A, Jaquet A, Ekouevi DK, Toure B, Coffie PA, Effi B, Messou E, Minga A,
Moh R, Kone M: Cervical cancer screening by visual inspection in Cote
d'Ivoire, operational and clinical aspects according to HIV status. BMC
Public Health 2012, 12(1):237.
42. Weinhardt LS, Carey MP, Johnson BT, Bickham NL: Effects of HIV
counseling and testing on sexual risk behavior: a meta-analytic review
of published research, 1985–1997. Am J Public Health 1999,
89(9):1397–1405.
43. Singh DK, Anastos K, Hoover DR, Burk RD, Shi Q, Ngendahayo L, Mutimura E,
Cajigas A, Bigirimani V, Cai X, Rwamwejo J, Vuolo M, Cohen M, Castle PE:
Ononogbu et al. BMC Public Health 2013, 13:582 Page 9 of 10
http://www.biomedcentral.com/1471-2458/13/582Human Papillomavirus Infection and Cervical Cytology in HIV‐Infected and
HIV‐Uninfected Rwandan Women. JI n f e c tD i s2009, 199(12):1851–1861.
44. Anastos K, Hoover DR, Burk RD, Cajigas A, Shi Q, Singh DK, Cohen MH,
Mutimura E, Sturgis C, Banzhaf WC, Castle PE: Risk factors for cervical
precancer and cancer in HIV-infected, HPV-positive Rwandan women.
PLoS One 2010, 5(10):e13525.
45. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC,
Holmberg SD, Brooks JT: Incidence of types of cancer among HIV-infected
persons compared with the general population in the United States,
1992–2003. Ann Intern Med 2008, 148(10):728–736.
46. Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F, Russo A, Intrieri
T, Vercelli M, Zambon P: Pattern of cancer risk in persons with AIDS in
Italy in the HAART era. Br J Cancer 2009, 100(5):840–847.
47. Anderson J, Lu E, Sanghvi H, Kibwana S, Lu A: Cervical cancer screening
and prevention for HIV-infected women in the developing world. Mol
Biosyst 2010, 6:1162–1172.
48. US Cancer Statistics Working Group: United States Cancer Statistics: 1999–
2007 Incidence and Mortality Web-based Report, US Department of Health
and Human Services, Centers for Disease Control and Prevention, and
National Cancer Institute. Atlanta GA; 2010.
49. Gichangi PB, Bwayo J, Estambale B, De Vuyst H, Ojwang S, Rogo K, Abwao
H, Temmerman M: Impact of HIV infection on invasive cervical cancer in
Kenyan women. AIDS 2003, 17(13):1963–1968.
50. Moodley M, Moodley J, Kleinschmidt I: Invasive cervical cancer and human
immunodeficiency virus (HIV) infection: a South African perspective. Int J
Gynecol Cancer 2001, 11(3):194–197.
51. Harris TG, Burk RD, Palefsky JM, Massad LS, Bang JY, Anastos K, Minkoff H,
Hall CB, Bacon MC, Levine AM: Incidence of cervical squamous
intraepithelial lesions associated with HIV serostatus, CD4 cell counts,
and human papillomavirus test results. JAMA 2005, 293(12):1471–1476.
52. Cardillo M, Hagan R, Abadi J, Abadi MA: CD4 T-Cell count, viral load, and
squamous intraepithelial lesions in women infected with the human
immunodeficiency virus. Cancer Cytopathol 2001, 93(2):111–114.
53. Schiffman MH, Brinton LA: The epidemiology of cervical carcinogenesis.
Cancer 2006, 76(S10):1888–1901.
doi:10.1186/1471-2458-13-582
Cite this article as: Ononogbu et al.: Cervical cancer risk factors among
HIV-infected Nigerian women. BMC Public Health 2013 13:582.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ononogbu et al. BMC Public Health 2013, 13:582 Page 10 of 10
http://www.biomedcentral.com/1471-2458/13/582